<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496066</url>
  </required_header>
  <id_info>
    <org_study_id>CSP-002-03</org_study_id>
    <nct_id>NCT01496066</nct_id>
  </id_info>
  <brief_title>Calhoun Vision Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism</brief_title>
  <official_title>A Prospective Randomized Controlled Multi-Center Clinical Study to Evaluate the Safety and Effectiveness of the Light Adjustable Lens (LAL) in Subjects With Pre-Existing Corneal Astigmatism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calhoun Vision, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Calhoun Vision, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to evaluate the Calhoun Vision Light Adjustable Lens (LAL) and Light Delivery
      Device (LDD) for reducing astigmatism and improving uncorrected vision after implantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 3 medical device study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Reduction in Manifest Cylinder</measure>
    <time_frame>6 months</time_frame>
    <description>Percent reduction in manifest cylinder from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. Manifest cylinder refers to only the astigmatic or cylindrical component of an ophthalmic manifest refraction. For example if someone had a refraction of +0.50-1.00x090, the -1.00 is the manifest cylinder component. The reduction of the manifest cylinder is determined from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.
Only eyes that had cylinder in the range of treatment (&gt;=0.75 D) were included in the analysis. Therefore the number of participants analyzed for this outcome measure will not match the overall number of participants in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Absolute Reduction in MRSE</measure>
    <time_frame>6 months</time_frame>
    <description>Percent absolute reduction in Manifest Refraction Spherical Equivalent (MRSE) from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. It is used to describe an ophthalmic refraction with one number. It is defined as the (sphere)+ 0.5(cylinder). So, if you had a refraction of +1.00-1.00x090 the MRSE would be +0.50. If you had a refraction of +0.25-1.50x145 the MRSE would be -0.50. The absolute value of the MRSE is taken and its reduction is calculated from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.
Any eyes that had an MRSE of zero at Pre-Adjustment were excluded since it is not possible to divide by zero. Therefore the number participants analyzed for this outcome will differ from the number of overall participants in the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rotation of LAL Landmark Meridian to Anatomical Landmark at Pre-Adjustment and 6 Months Postop</measure>
    <time_frame>6 months</time_frame>
    <description>Number (%) of eyes with rotation of LAL meridian of ≤ 5 degrees from Pre-Adjustment to 6 months postop. This endpoint was achieved by taking dilated anterior segment photographs of the LAL at Pre-Adjustment and 6 months postop. The angular difference between a landmark on the LAL and an anatomical landmark on the subjects eye was measured. The same landmarks on the LAL and the subjects eye were used at each time point. The angular difference between the two time points was then determined. The overall number of participants analyzed differs from the other out outcome measures because some photographs were unusable due to inadequate lighting, user error, or equipment failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uncorrected Visual Acuity 20/20 or Better</measure>
    <time_frame>6 months</time_frame>
    <description>Percent of eyes with UCVA of 20/20 or better in the LAL treatment group at 6 months postoperatively was calculated to determine if it is significantly greater than the percent of eyes with UCVA of 20/20 or better in the monofocal control group at 6 months postoperatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Reduction in Cylinder by Cylinder Adjustment Stratum (0.75D-1.25D)</measure>
    <time_frame>6 months</time_frame>
    <description>Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group. Results were to be evaluated for each cylinder adjustment stratum (0.75-1.25 D and 1.50-2.00 D) separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Reduction in Cylinder by Cylinder Adjustment Stratum (&gt;1.25D)</measure>
    <time_frame>6 months</time_frame>
    <description>Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to Pre-Adjustment in the LAL group/17-21 days postoperative in the control group. The results only include eyes that had greater than 1.25D of refractive cylinder at Pre-Adjustment in the LAL group/17-21 days postoperative in the control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Absolute Reduction in Manifest Refraction Spherical Equivalent (MRSE) for Eyes With &lt;0.75 D Cylinder Postoperatively</measure>
    <time_frame>6 months</time_frame>
    <description>For eyes with &lt;0.75 D of cylinder at pre-adjustment (LAL)/17-21 days (control group), percent mean absolute reduction in MRSE by subject in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in mean absolute MRSE in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean BSCVA</measure>
    <time_frame>6 months</time_frame>
    <description>Mean BSCVA for the &quot;best case&quot; cohort (no macular problems) at 6 months postoperatively was compared between the LAL treatment group and the monofocal control group. Endpoint success was to be achieved if the difference in mean BSCVA between the LAL cohort and the monofocal control group is within 1 line (0.1 LogMAR) (non-inferiority margin or delta).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">600</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>LAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LAL implanted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Monofocal control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monofocal control IOL implanted</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAL (Light Adjustable Lens) and Light Deliver Device (LDD)</intervention_name>
    <description>LAL implanted and adjusted with LDD</description>
    <arm_group_label>LAL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monofocal control IOL</intervention_name>
    <description>Commercially available monofocal intraocular lens (IOL)</description>
    <arm_group_label>Monofocal control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing cataract surgery and be willing to have LAL or commercially available IOL
             implanted

          -  Pre-operative regular corneal astigmatism of &gt;= 0.75 diopters and &lt;= 2.0 diopters

          -  Best spectacle corrected visual acuity reduced to 20/40 or worse with or without glare

          -  Projected best spectacle corrected visual acuity of 20/20 or better

          -  Clear intraocular media other than cataract

          -  Potentially good vision in fellow eye

          -  Fully dilated pupil of &gt;= 7.0 mm

        Exclusion Criteria:

          -  Zonular laxity or dehiscence

          -  Pseudoexfoliation

          -  Age related macular degeneration

          -  Retinal degenerative disorder

          -  Diabetes with any evidence of retinopathy

          -  Glaucomatous optic neuropathy, uveitis, significant anterior segment pathology,
             keratoconus

          -  Corneal dystrophy, previous corneal or intraocular surgery

          -  Complications during cataract surgery

          -  Serious co-morbid conditions

          -  Systemic medications that my increase UV sensitivity

          -  Irregular astigmatism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolstan &amp; Goldberg Eye Associates</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newsom Eye</name>
      <address>
        <city>Sebring</city>
        <state>Florida</state>
        <zip>33870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arbor Centers for Eye Care</name>
      <address>
        <city>Orland Park</city>
        <state>Illinois</state>
        <zip>60467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgeons of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jones Eye Clinic</name>
      <address>
        <city>Sioux City</city>
        <state>Iowa</state>
        <zip>51104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Vision &amp; Laser Center</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants, PA</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Consultants, Ltd.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EyeSight Ophthalmic Services, PA</name>
      <address>
        <city>Somersworth</city>
        <state>New Hampshire</state>
        <zip>03878</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Vision Center</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Eye Clinic</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vance Thompson Vision</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Consultants of Texas</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Focal Point Vision</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoopes Vision</name>
      <address>
        <city>Draper</city>
        <state>Utah</state>
        <zip>84020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <results_first_submitted>December 29, 2017</results_first_submitted>
  <results_first_submitted_qc>February 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2018</results_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Astigmatism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LAL Implant</title>
          <description>LAL implanted
LAL (Light Adjustable Lens) and Light Deliver Device (LDD): LAL implanted and adjusted with LDD</description>
        </group>
        <group group_id="P2">
          <title>Monofocal Control</title>
          <description>Monofocal control IOL implanted
Monofocal control IOL: Commercially available monofocal intraocular lens (IOL)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="391"/>
                <participants group_id="P2" count="188"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Explant</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LAL Implant</title>
          <description>LAL implanted
LAL (Light Adjustable Lens) and Light Deliver Device (LDD): LAL implanted and adjusted with LDD</description>
        </group>
        <group group_id="B2">
          <title>Monofocal Control</title>
          <description>Monofocal control IOL implanted
Monofocal control IOL: Commercially available monofocal intraocular lens (IOL)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="403"/>
            <count group_id="B2" value="197"/>
            <count group_id="B3" value="600"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="7.9"/>
                    <measurement group_id="B2" value="66.6" spread="7.2"/>
                    <measurement group_id="B3" value="66.2" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="344"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="385"/>
                    <measurement group_id="B2" value="190"/>
                    <measurement group_id="B3" value="575"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="383"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="571"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Right Eye</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Eye</title>
          <units>Eyes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Reduction in Manifest Cylinder</title>
        <description>Percent reduction in manifest cylinder from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. Manifest cylinder refers to only the astigmatic or cylindrical component of an ophthalmic manifest refraction. For example if someone had a refraction of +0.50-1.00x090, the -1.00 is the manifest cylinder component. The reduction of the manifest cylinder is determined from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.
Only eyes that had cylinder in the range of treatment (&gt;=0.75 D) were included in the analysis. Therefore the number of participants analyzed for this outcome measure will not match the overall number of participants in the study.</description>
        <time_frame>6 months</time_frame>
        <population>ITT. Only eyes that had cylinder in the range of treatment (&gt;=0.75 D) were included in the analysis. Therefore the number of participants analyzed for this outcome measure will not match the overall number of participants in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens Implanted</title>
            <description>Randomized to have the Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Control IOL Implanted</title>
            <description>Randomized to have the monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction in Manifest Cylinder</title>
          <description>Percent reduction in manifest cylinder from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. Manifest cylinder refers to only the astigmatic or cylindrical component of an ophthalmic manifest refraction. For example if someone had a refraction of +0.50-1.00x090, the -1.00 is the manifest cylinder component. The reduction of the manifest cylinder is determined from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.
Only eyes that had cylinder in the range of treatment (&gt;=0.75 D) were included in the analysis. Therefore the number of participants analyzed for this outcome measure will not match the overall number of participants in the study.</description>
          <population>ITT. Only eyes that had cylinder in the range of treatment (&gt;=0.75 D) were included in the analysis. Therefore the number of participants analyzed for this outcome measure will not match the overall number of participants in the study.</population>
          <units>percent reduction in manifest cylinder</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.6" lower_limit="71.1" upper_limit="78.1"/>
                    <measurement group_id="O2" value="19.9" lower_limit="10.9" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Absolute Reduction in MRSE</title>
        <description>Percent absolute reduction in Manifest Refraction Spherical Equivalent (MRSE) from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. It is used to describe an ophthalmic refraction with one number. It is defined as the (sphere)+ 0.5(cylinder). So, if you had a refraction of +1.00-1.00x090 the MRSE would be +0.50. If you had a refraction of +0.25-1.50x145 the MRSE would be -0.50. The absolute value of the MRSE is taken and its reduction is calculated from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.
Any eyes that had an MRSE of zero at Pre-Adjustment were excluded since it is not possible to divide by zero. Therefore the number participants analyzed for this outcome will differ from the number of overall participants in the study.</description>
        <time_frame>6 months</time_frame>
        <population>ITT. Any eyes that had an MRSE of zero at Pre-Adjustment were excluded since it is not possible to divide by zero. Therefore the number participants analyzed for this outcome will differ from the number of overall participants in the study.</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Eyes randomized to have Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Monofocal Control IOL</title>
            <description>Eyes randomized to have monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Absolute Reduction in MRSE</title>
          <description>Percent absolute reduction in Manifest Refraction Spherical Equivalent (MRSE) from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop. It is used to describe an ophthalmic refraction with one number. It is defined as the (sphere)+ 0.5(cylinder). So, if you had a refraction of +1.00-1.00x090 the MRSE would be +0.50. If you had a refraction of +0.25-1.50x145 the MRSE would be -0.50. The absolute value of the MRSE is taken and its reduction is calculated from Pre-Adjustment (LAL) or 17-21 days post-op (control) to 6 months postop.
Any eyes that had an MRSE of zero at Pre-Adjustment were excluded since it is not possible to divide by zero. Therefore the number participants analyzed for this outcome will differ from the number of overall participants in the study.</description>
          <population>ITT. Any eyes that had an MRSE of zero at Pre-Adjustment were excluded since it is not possible to divide by zero. Therefore the number participants analyzed for this outcome will differ from the number of overall participants in the study.</population>
          <units>percentage of reduction in MRSE</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="380"/>
                <count group_id="O2" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" lower_limit="43.8" upper_limit="59.1"/>
                    <measurement group_id="O2" value="10.4" lower_limit="-3.8" upper_limit="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rotation of LAL Landmark Meridian to Anatomical Landmark at Pre-Adjustment and 6 Months Postop</title>
        <description>Number (%) of eyes with rotation of LAL meridian of ≤ 5 degrees from Pre-Adjustment to 6 months postop. This endpoint was achieved by taking dilated anterior segment photographs of the LAL at Pre-Adjustment and 6 months postop. The angular difference between a landmark on the LAL and an anatomical landmark on the subjects eye was measured. The same landmarks on the LAL and the subjects eye were used at each time point. The angular difference between the two time points was then determined. The overall number of participants analyzed differs from the other out outcome measures because some photographs were unusable due to inadequate lighting, user error, or equipment failure.</description>
        <time_frame>6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Eyes randomized to be implanted with the Light Adjustable Lens</description>
          </group>
        </group_list>
        <measure>
          <title>Rotation of LAL Landmark Meridian to Anatomical Landmark at Pre-Adjustment and 6 Months Postop</title>
          <description>Number (%) of eyes with rotation of LAL meridian of ≤ 5 degrees from Pre-Adjustment to 6 months postop. This endpoint was achieved by taking dilated anterior segment photographs of the LAL at Pre-Adjustment and 6 months postop. The angular difference between a landmark on the LAL and an anatomical landmark on the subjects eye was measured. The same landmarks on the LAL and the subjects eye were used at each time point. The angular difference between the two time points was then determined. The overall number of participants analyzed differs from the other out outcome measures because some photographs were unusable due to inadequate lighting, user error, or equipment failure.</description>
          <population>ITT</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="358"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="93.5" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Uncorrected Visual Acuity 20/20 or Better</title>
        <description>Percent of eyes with UCVA of 20/20 or better in the LAL treatment group at 6 months postoperatively was calculated to determine if it is significantly greater than the percent of eyes with UCVA of 20/20 or better in the monofocal control group at 6 months postoperatively.</description>
        <time_frame>6 months</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Randomized to have the Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Monofocal Control IOL</title>
            <description>Randomized to have a Monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Uncorrected Visual Acuity 20/20 or Better</title>
          <description>Percent of eyes with UCVA of 20/20 or better in the LAL treatment group at 6 months postoperatively was calculated to determine if it is significantly greater than the percent of eyes with UCVA of 20/20 or better in the monofocal control group at 6 months postoperatively.</description>
          <population>ITT</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="391"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.1"/>
                    <measurement group_id="O2" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Reduction in Cylinder by Cylinder Adjustment Stratum (0.75D-1.25D)</title>
        <description>Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group. Results were to be evaluated for each cylinder adjustment stratum (0.75-1.25 D and 1.50-2.00 D) separately.</description>
        <time_frame>6 months</time_frame>
        <population>Eyes in ITT with 0.75-1.25 D cylinder prior to light treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Randomized to have the Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Monofocal Control IOL</title>
            <description>Randomized to have the monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reduction in Cylinder by Cylinder Adjustment Stratum (0.75D-1.25D)</title>
          <description>Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group. Results were to be evaluated for each cylinder adjustment stratum (0.75-1.25 D and 1.50-2.00 D) separately.</description>
          <population>Eyes in ITT with 0.75-1.25 D cylinder prior to light treatment</population>
          <units>percent reduction in cylinder</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="33.1"/>
                    <measurement group_id="O2" value="18.6" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Reduction in Cylinder by Cylinder Adjustment Stratum (&gt;1.25D)</title>
        <description>Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to Pre-Adjustment in the LAL group/17-21 days postoperative in the control group. The results only include eyes that had greater than 1.25D of refractive cylinder at Pre-Adjustment in the LAL group/17-21 days postoperative in the control group</description>
        <time_frame>6 months</time_frame>
        <population>ITT eyes with &gt;1.25 D of cylinder prior to light treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Randomized to have the Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Monofocal Control IOL</title>
            <description>Randomized to have the monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Reduction in Cylinder by Cylinder Adjustment Stratum (&gt;1.25D)</title>
          <description>Percent reduction in absolute manifest cylinder in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in absolute cylinder in the monofocal control group at 6 months postoperatively compared to Pre-Adjustment in the LAL group/17-21 days postoperative in the control group. The results only include eyes that had greater than 1.25D of refractive cylinder at Pre-Adjustment in the LAL group/17-21 days postoperative in the control group</description>
          <population>ITT eyes with &gt;1.25 D of cylinder prior to light treatment</population>
          <units>percent reduction in cylinder</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.5" spread="20.7"/>
                    <measurement group_id="O2" value="23.1" spread="32.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Absolute Reduction in Manifest Refraction Spherical Equivalent (MRSE) for Eyes With &lt;0.75 D Cylinder Postoperatively</title>
        <description>For eyes with &lt;0.75 D of cylinder at pre-adjustment (LAL)/17-21 days (control group), percent mean absolute reduction in MRSE by subject in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in mean absolute MRSE in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group.</description>
        <time_frame>6 months</time_frame>
        <population>Eyes in ITT with &lt;0.75 D of cylinder prior to light treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Randomized to have the Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Monofocal Control IOL</title>
            <description>Randomized to have the monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Absolute Reduction in Manifest Refraction Spherical Equivalent (MRSE) for Eyes With &lt;0.75 D Cylinder Postoperatively</title>
          <description>For eyes with &lt;0.75 D of cylinder at pre-adjustment (LAL)/17-21 days (control group), percent mean absolute reduction in MRSE by subject in the LAL treatment group was calculated to determine if it is significantly greater than the percent reduction in mean absolute MRSE in the monofocal control group at 6 months postoperatively compared to pre-adjustment in the LAL group/17-21 days postoperative in the control group.</description>
          <population>Eyes in ITT with &lt;0.75 D of cylinder prior to light treatment</population>
          <units>percent absolute reduction in MRSE</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.2" spread="76.3"/>
                    <measurement group_id="O2" value="27.2" spread="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.0318</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean BSCVA</title>
        <description>Mean BSCVA for the “best case” cohort (no macular problems) at 6 months postoperatively was compared between the LAL treatment group and the monofocal control group. Endpoint success was to be achieved if the difference in mean BSCVA between the LAL cohort and the monofocal control group is within 1 line (0.1 LogMAR) (non-inferiority margin or delta).</description>
        <time_frame>6 months</time_frame>
        <population>ITT population best case cohort with no macular problems</population>
        <group_list>
          <group group_id="O1">
            <title>Light Adjustable Lens</title>
            <description>Randomized to have the Light Adjustable Lens implanted</description>
          </group>
          <group group_id="O2">
            <title>Monofocal Control IOL</title>
            <description>Randomized to have the Monofocal control IOL implanted</description>
          </group>
        </group_list>
        <measure>
          <title>Mean BSCVA</title>
          <description>Mean BSCVA for the “best case” cohort (no macular problems) at 6 months postoperatively was compared between the LAL treatment group and the monofocal control group. Endpoint success was to be achieved if the difference in mean BSCVA between the LAL cohort and the monofocal control group is within 1 line (0.1 LogMAR) (non-inferiority margin or delta).</description>
          <population>ITT population best case cohort with no macular problems</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="390"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.066" spread="0.083"/>
                    <measurement group_id="O2" value="-0.029" spread="0.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>a two-group t-test of equivalence in means was used</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>99</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Light Adjustable Lens</title>
          <description>Randomized to have the Light Adjustable Lens implanted</description>
        </group>
        <group group_id="E2">
          <title>Monofocal Control IOL</title>
          <description>Randomized to have the Monofocal control IOL implanted</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood clots due to lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain with pacemaker</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Heart palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Heart surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Triple bypass surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Herpetic Keratouveitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Persistent Induced Tritan Color Anomaly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Cystoid Macular Edema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="403"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Horseshoe retinal tear with vitreous hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hypopyon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Surgical complication</sub_title>
                <description>Surgical complication including anterior segment bleeding, vitreous loss, and posterior capsule and zonular rupture</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Secondary surgical intervention</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Phytotoxic retinal damage causing temporary loss of BSCVA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Persistent induced erythropsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Persistent unanticipated increase refractive error</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Intraoperative capsular tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Broken wrist</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hospitalization due to syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hospitalization due to low blood pressure and syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hospitalization due to dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hospitalization due to infection after knee surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to concussion with subdural hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Liver cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Malignant neuroendocrine tumors</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Hospitalization due to emphysema/COPD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Broken blood vessel in brain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="292" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="125" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior chamber cells</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="403"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Anterior chamber flare</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="403"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="403"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Corneal edema central</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="403"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>corneal edema wound</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="403"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Posterior capsular opacity</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="403"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Raised IOP not requiring treatment</sub_title>
                <counts group_id="E1" events="32" subjects_affected="32" subjects_at_risk="403"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Raised IOP requiring treatment</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="403"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="197"/>
              </event>
              <event>
                <sub_title>Superficial punctate keratitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="403"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="197"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maureen O'Connell Vice President, Regulator and Clinical Affairs</name_or_title>
      <organization>RxSight, Inc.</organization>
      <phone>978-207-12415</phone>
      <email>moconnell@rxsight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

